About Infinity

Julian Adams, Ph.D., is president, research and development. Dr. Adams is responsible for the full spectrum of Infinity's drug discovery, preclinical and clinical development strategy, and regulatory affairs activities. Prior to joining Infinity in 2003, Dr. Adams was the senior vice president, drug discovery and development at Millennium Pharmaceuticals. In this capacity, he had global responsibility for multiple drug discovery programs, including the successful discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy. He joined Millennium through its acquisition of LeukoSite in 1999 where he was senior vice president research and development. Dr. Adams joined LeukoSite as a result of its acquisition of ProScript, Inc., where he had served as a member of the founding management team, executive vice president of research and development, and a member of the board of directors. Earlier in his career, Dr. Adams served in various positions, including director, medicinal chemistry at Boehringer Ingelheim, where he successfully discovered the drug Viramune® (nevirapine) for HIV. Also, from 1982-1987, he was a medicinal chemist at Merck.

Dr. Adams has received many awards, the 2012 Warren Alpert Foundation Prize for his role in the discovery and development of bortezomib, the 2012 C. Chester Stock Award Lectureship from Memorial Sloan-Kettering Cancer Center, and the 2001 Ribbon of Hope Award for Velcade® from the International Myeloma Foundation. Dr. Adams is an inventor of more than 40 patents and has authored over 100 papers and book chapters in peer-reviewed journals. He is the editor of Proteasome Inhibition in Cancer Therapy, published in July 2004.

Dr. Adams received his B.S. from McGill University and his Ph.D. from the Massachusetts Institute of Technology in the field of synthetic organic chemistry. He also received the degree of Doctor of Science, honoris causa, from McGill University in 2012.

Lawrence E. Bloch, MD, JD is executive vice president, chief financial officer and chief business officer. Prior to joining Infinity in 2012, Dr. Bloch served as chief executive officer of NeurAxon, Inc., a company focused on developing next-generation pain therapeutics, from 2007 to 2011. Previously, he served as chief business officer and chief financial officer of NitroMed, Inc., raising $150 million in equity and $20 million in venture debt to support the commercial launch of BiDil®. From 1999 to 2004, he served as chief financial officer and vice president of business development, of Applied Molecular Evolution, Inc., leading the company’s $101 million initial public offering and $420 million merger with Eli Lilly and Company.

Dr. Bloch began his career as an emergency medicine resident physician at Massachusetts General Hospital and Brigham & Woman’s Hospital. He holds a J.D. from Harvard Law School, an M.D. from Harvard Medical School and an M.B.A from Harvard Business School.

Joshua Hamermesh is vice president, business and corporate development. He is responsible for the company's corporate strategy and business development initiatives. Prior to joining Infinity, Mr. Hamermesh held the position of senior vice president, strategy and corporate development at Pervasis Therapeutics, Inc. where he led strategic partnering initiatives for the company's product development portfolio. Prior to that, he served as vice president, commercial and business development at Molecular Insight Pharmaceuticals, Inc. where he completed numerous in-licensing transactions and supported the company's initial public offering. Mr. Hamermesh began his biotechnology career at Genzyme Corporation, where he served as chief operating officer of MG Biotherapeutics, a joint venture with Medtronic, Inc., after holding positions of increasing responsibility in the marketing and business development groups. He also served as a business strategy consultant to the industry at the Monitor Company.

Mr. Hamermesh received his M.B.A. from Harvard Business School and his B.A. in Economics from Amherst College.

John J. Keilty is vice president, information technology and informatics. Mr. Keilty is responsible for information systems, software development, structural biology, bioinformatics, and clinical informatics. Prior to joining Infinity in 2002, Mr. Keilty was an early member of Millennium Pharmaceuticals where he held various roles of increasing responsibility, including senior manager of molecular research services with broad ownership for the creation, management, implementation and transfer of much of the company’s core genomic technologies. Many of the developed software applications, algorithms and laboratory procedures were transferred to Millennium’s corporate partners as part of larger business collaborations. Before Millennium, Mr. Keilty worked in the Howard Hughes lab of Michael Green at the University of Massachusetts Medical Center, focusing on basic research in transcription and gene splicing.

Mr. Keilty received his B.A. in biology from Clark University and his M.S. in bioinformatics from Brandeis University.

Jeanette W. Kohlbrenner is vice president, human resources. She is responsible for Infinity’s human resource and organizational development functions. Ms. Kohlbrenner joined Infinity in 2006 with over 15 years of experience in senior human resource roles with life science and medical device companies, ranging from start-up to fully commercial, global organizations. Prior to joining Infinity, Ms. Kohlbrenner was the business unit director of human resources for Cambrex Biosciences, with responsibilities for pharmaceutical development and manufacturing locations in the United States. Before Cambrex, Ms. Kohlbrenner worked at Syntonix Pharmaceuticals, where she served as director of human resources and a key member of the senior team working to build the company. Ms. Kohlbrenner also held human resource roles with Genetics Institute/Wyeth Pharmaceuticals, and Hewlett-Packard’s Medical Device business (now Philips Medical). Early in her career, Ms. Kohlbrenner was a compensation and performance management consultant with William Mercer, a global leader in human resource consulting.

Ms. Kohlbrenner received her M.B.A. from Babson College and her B.A. in mathematics from Holy Cross.

John J. Lee is vice president, pharmaceutical development. He is responsible for chemistry, manufacturing and control (CMC), analytical sciences, formulation sciences, and clinical supply and distribution for Infinity’s drug candidates. Prior to joining Infinity in 2001, Mr. Lee was a new product manager at Corning Life Science where he was responsible for developing new life science products from Corning research and technologies. Before Corning, Mr. Lee was an early member of Millennium Pharmaceuticals and played a key role in the successful positional cloning of the mouse obesity gene tubby before taking on various roles of increasing responsibility, including project lead for an ovarian cancer diagnostic program, a collaboration with Becton Dickenson, Mayo Clinic, and MD Anderson utilizing Millennium’s core genomic and proteomic technologies to develop a molecular screening test to detect early stage ovarian cancer. Prior to Millennium, Mr. Lee worked in the Developmental Chronobiology lab of Steven Reppert at Massachusetts General Hospital focused on cloning G-protein coupled receptors and circadian biology.

Mr. Lee received his S.B. in Materials Science and Engineering from MIT.

Vito J. Palombella, Ph.D., has served as Infinity’s chief scientific officer since 2010. He is responsible for the company’s drug discovery and preclinical development activities. Prior to his role as chief scientific officer, Dr. Palombella was vice president, biology and then vice president, drug discovery at Infinity. Prior to joining Infinity in 2004, Dr. Palombella served as director of molecular biology and protein chemistry at Syntonix Pharmaceuticals where he was responsible for improving and expanding its core Fc receptor-mediated drug delivery technology. Before joining Syntonix, Dr. Palombella served as senior director of cell and molecular biology at Millennium Pharmaceuticals, which he joined through its acquisition of LeukoSite in 1999. Prior to its acquisition by LeukoSite, Dr. Palombella held a number of positions at ProScript, Inc. While at ProScript, LeukoSite and Millennium, Dr. Palombella was involved in the discovery and development of Velcade® (bortezomib), a proteasome inhibitor for cancer therapy. He also managed a number of additional projects, including research into NF-KB regulation.

Dr. Palombella received his B.S. in microbiology from Rutgers University and his M.S. and Ph.D. in viral oncology and immunology from the New York University Medical Center. He was also a post-doctoral fellow at Harvard University in the laboratory of Tom Maniatis, Ph.D.

Adelene Q. Perkins has served as Infinity's president and chief executive officer since 2009 and as board chair since 2012. Ms. Perkins first joined Infinity as chief business officer in 2002 and was named president in 2008. She has played an integral role in building the company, leading its transition from a platform to a product-based organization. She was the principal figure in structuring and restructuring Infinity's strategic relationships which have played a critical role in developing the company’s current product portfolio. Ms. Perkins has more than 25 years of international business experience in the biopharmaceutical industry, focused on building and leading high-caliber, cross-functional teams, corporate strategy, licensing and business development, strategic finance, and product life cycle management.

Ms. Perkins joined Infinity from TransForm Pharmaceuticals where she was an early member of the management team that built the company prior to its acquisition by J&J. Prior to TransForm, she was vice president of emerging businesses and the cofounder and general manager of the DiscoverEaseT business unit at Genetics Institute, now part of Pfizer. She also formed and served as chief executive officer of MetaMorphix, a joint venture between Genetics Institute and Johns Hopkins University. She joined GI from Bain & Company where she spent seven years providing strategic and operational advice to clients in the healthcare industry. Ms. Perkins received her M.B.A. from Harvard Business School and her B.S. in chemical engineering from Villanova University. She is vice chair of the board of Project Hope and a member of the Villanova University College of Engineering Advisory Board.

Margaret A. Read, Ph.D. is vice president of product development at Infinity, where she has worked since February 2005. She is responsible for providing strategic support for product and portfolio decisions. While at Infinity, Dr. Read was instrumental in the development of saridegib as the company’s product development leader for the Hedgehog pathway program. Prior to that appointment, Dr. Read was senior director of Infinity’s Cancer Biology Group. Dr. Read previously held the position of director, molecular and cellular oncology at Millennium Pharmaceuticals where she served as the discovery leader on the Velcade® product development team. Dr. Read has also served as Instructor and Research Fellow at the Harvard Medical School, Brigham & Women’s Hospital Division of Vascular Research and did Postdoctoral work at Vanderbilt University, Nashville, Tennessee where she earned a Ph.D. in Pathology.

Dr. Read completed Postdoctoral work at Vanderbilt University, Nashville, Tennessee where she earned a Ph.D. in Pathology.

Pedro Santabarbara, M.D., Ph.D., is chief medical officer. He is responsible for developing and implementing clinical trial strategies for Infinity’s pipeline as well as overseeing the company’s clinical operations and drug safety programs. Prior to joining Infinity in 2010, Dr. Santabarbara spent five years with PharmaMar, where he most recently led the development and approval of Yondelis® (trabectedin). Prior to PharmaMar, he served as vice president of clinical research oncology at OSI Pharmaceuticals, Inc., where he led the successful approval of Tarceva® (erlotinib). Before joining OSI, Dr. Santabarbara led development activities for Campath® (alemtuzumab) at ILEX Oncology, Inc. Earlier in his career, Dr. Santabarbara was also employed at Rhone Poulenc Rorer where he led the North American clinical development of Taxotere® (docetaxel), which he drove to approval in breast cancer and designed the strategy for non-small cell lung cancer. He also contributed to the development of Taxol® (paclitaxel) while at Bristol-Myers Squibb. Dr. Santabarbara’s experience also includes 14 years in research and clinical practice.

Dr. Santabarbara earned his M.D. and Ph.D. from University of Barcelona, School of Medicine.

Tamyra A. Toole, Esq., is vice president, regulatory affairs and quality assurance. She is responsible for the global regulatory strategy for the development of Infinity’s drug candidates, and the company’s compliance with regulatory standards and guidelines. Prior to joining Infinity in 2008, Ms. Toole held the role of senior director, regulatory affairs at NitroMed, Inc. and has previously held positions in regulatory affairs and quality assurance at Wyeth Pharmaceuticals, Millennium Pharmaceuticals and Organogenesis, Inc. She has experience developing drugs, biologics and medical devices in the oncology, hematology, cardiovascular, and plastic and reconstructive therapeutic areas. Prior to working in drug development, Ms. Toole held various positions in the Department of Nursing at Brigham and Women’s Hospital.

Ms. Toole received her J.D. from the Catholic University of America, Columbus School of Law and her B.S. in nursing from Villanova University.

Winselow S. Tucker Jr. is vice president, marketing. Mr. Tucker is responsible for bringing commercial insights to the company’s product development decisions and business development initiatives, as well as leading Infinity’s new product marketing activities. Mr. Tucker has 15 years of comprehensive commercial pharmaceutical experience in sales, new product marketing and brand leadership in both global and country level positions across a number of therapeutic areas. Prior to joining Infinity in 2010, Mr. Tucker held roles of increasing responsibility at Novartis Pharmaceuticals in the U.S .and Global operations, most recently at Novartis Oncology where he was the global brand leader for the company’s Gleevec® (imatinib) and Tasigna® (nilotinib) franchise. At Novartis, Mr. Tucker also led the launch for those products in several oncology indications.

Mr. Tucker also possesses strong brand leadership experience having led the U.S. launch of Tasigna, successfully integrating the product into the Novartis CML franchise, before going on to lead the Gleevec and Tasigna franchise in the U.S. Mr. Tucker joined Novartis Pharmaceuticals in Europe where he developed global marketing and launch strategies for a leading anti-hypertensive drug. Prior to Novartis, Mr. Tucker spent several years in commercial roles at GlaxoSmithKline Pharmaceuticals, where he played a critical role in the successful launch of a blockbuster diabetes drug and had responsibility for commercial decisions on a portfolio of new products in development across various indications and therapeutic areas.

Mr. Tucker received his M.B.A. in marketing from Indiana University and earned his B.A. in business administration from Howard University.